* FDA to ask panel about diabetes, other issues
* FDA reviewer sees benefit outweighing risk
* Fatal stomach problems called ‘chance finding’
WASHINGTON, Dec 11 (Reuters) - U.S. regulators will ask an advisory panel to consider findings of diabetes and other safety issues as they weigh wider use of AstraZeneca Plc’s(AZN.L) cholesterol-lowering pill Crestor, documents released on Friday said.
